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Managing expense and expectation in a treatment revolution: Problematizing prioritisation through 
an exploration of hepatitis C treatment ‘benefit’.   
 
ABSTRACT 
Background: Direct-acting antivirals (DAAs) have transformed the hepatitis C (HCV) treatment 
landscape. These highly effective drugs are, however, not available to all. In a context of DAA 
rationing, clinicians are advised to “manage patient expectations” about the benefits of a HCV cure. 
This directive particularly pertains to people with minimal liver damage and those who have ceased 
injecting: populations negated in contemporary prioritisation debates. 
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Methods: This paper engages with the assumptions underpinning HCV treatment prioritisation 
discourses to explore the concept of treatment ‘benefit’ from patient perspectives. Data are from a 
qualitative longitudinal study exploring treatment transitions and decision-making from 2012-2015. 
Participants comprised 28 people living with HCV, ten treatment providers and eight stakeholders, 
based in London, United Kingdom (UK). One hundred hours of clinic observations were conducted at 
two HCV treatment hospitals. Thematic analyses pertaining to treatment expectation and outcome 
inform this paper. 
Findings:  Twenty-two participants commenced treatment.  The majority who were unable to access 
DAAs chose to commence interferon-based treatment immediately rather than wait. Participants 
accounted for treatment urgency in relation to three interrelated narratives of hope and 
expectation. HCV treatment promised: social reconnection; social redemption and a return to 
‘normality’. For many with successful treatment outcomes, these benefits appeared to be realised.  
Conclusion: The DAA era heralds a discursive shift: from ‘managing [interferon] risk and difficulty’ to 
‘managing [DAA] expense and expectation’. Calls to ‘manage patient expectations’ about the 
benefits of HCV cure are predicated on clinical benefits only, negating the social impacts of living 
with HCV. The public health priorities commonly articulated in treatment prioritisation debates are 
not consistent with those of people managing illness in their daily lives. During this ‘treatment 
revolution’ there is a need to be cognisant of the multiple publics living with the virus and the 
treatment needs of those who do not fit population-health scenarios. 
 
 
Keywords: hepatitis C; treatment benefit; prioritisation; rationing; patient expectations; qualitative 
research. 
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INTRODUCTION 
 
The hepatitis C virus (HCV) treatment landscape has been transformed by the recent development 
and licencing of direct-acting antiviral (DAA) treatments. Highly effective, tolerable, and simple to 
deliver, DAAs have been heralded as a therapeutic revolution, portending the global “end of HCV” 
(Sussman, Remien, & Kanwal, 2014), and enabling “eradication in the United Kingdom by 2030” 
(Williams et al., 2014). Given that 130-150 million people live with chronic HCV globally, with 
217,000 situated in the United Kingdom (UK), eradication is not a modest aspiration. Particularly as 
these revolutionary drugs are not available for all. Pharmaceutical pricing is a primary barrier to 
widespread access, with list prices for DAA regimes in the region of £39,000 per 12-week course in 
the UK and $83,000 in the United States (US). In the US and Canada, DAA treatment eligibility is 
commonly restricted to people with advanced liver fibrosis (Burua, 2015; Marshall et al., 2016). In 
the UK, DAA access is limited to 10,000 people per year, with the National Health Service taking an 
unprecedented step in restricting treatments recommended as ‘cost-effective’ by their national 
guidance body (National Institute of Health and Care Excellence, 2015). Only a few countries (such as 
Australia and France) publicly subsidise these treatments for all, without disease stage restriction. 
Consequently, widespread enthusiasm for the DAA “pharmacological revolution” is tempered with 
debate about fiscal management and rationing modalities (Doyle et al., 2015; Hickman et al., 2016; 
Martin et al., 2016). 
 
Pharmaceutical rationing acts to shape in the present the future health and wellbeing of specific 
populations (Novas, 2006). Who these populations are and how their futures are constructed 
depends on the vision embraced (Hedgecoe & Martin, 2003). Two visions, or HCV treatment 
prioritisation scenarios, dominate the literature, each targeting specific populations. The first: scale 
up and prioritise DAA treatment for people with advanced liver disease (measured by fibrosis stage), 
thus curtailing severe liver morbidity (SLM). The second: scale up and prioritise DAA treatment for 
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people who inject drugs (PWID), thus reducing incident infections and population prevalence (Innes, 
Goldberg et al., 2014; Martin et al., 2016). The two visions are not mutually exclusive and are often 
conceptualised as a step-wise process, with health systems ideally encompassing both aims (Doyle et 
al., 2015: 1068).  
 
Of interest are the evidence and assumptions drawn on and created by these visions and the 
populations obscured or negated in this process.  Discourses of mathematical modelling, including in 
relation to HCV treatment affordability, cost-effectiveness, and benefit, play a central role in 
determining prioritisation debate. For example, Innes, Goldberg and colleagues (2014) model the 
scenarios outlined above (reducing SLM vs incident infections) asking of their audience “which public 
health outcomes do we value the most?”. They recommend that people with mild fibrosis who 
never, or no longer, inject drugs, are directed away from DAA access, as HCV cure among this group 
does not contribute to the aforementioned public health outcomes (cf., Martin et al., 2016). Given 
patient expectation and the promise of highly effective and tolerable DAAs, how might this de-
prioritisation directive play out in practice?  
 
The authors advise that clinicians practice patient ‘expectation management’, as: “more realistic 
expectations may lead to patients making more conservative treatment choices if the benefits on 
offer are accepted to be modest” (Innes, Goldberg, Dillon et al., 2014, emphasis added). Here, a 
specific clinical and epidemiological conceptualisation of treatment ‘benefit’ is drawn on: the 
attainment of additional life years and healthy life years. A simulation model calculating these 
outcomes finds that the benefits of a SVR (sustained virological response or HCV ‘cure’) for older 
individuals (~60 years) are minimal with only a <3% chance of additional life years and healthy life 
years, whereas the benefits of an SVR for younger individuals (~30 years) with cirrhosis are high, at 
>55% (Innes, Goldberg, Dusheiko et al., 2014). Notably, the model is described as measuring “patient 
important benefits”, illustrating a slippage between and conflation of specific clinical benefits with 
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broader social and experiential benefits. A similar conflation occurs in a BMJ article, which states: 
“Since most people infected with HCV never develop symptoms and will die from other causes, 
exposing them to the harms of [DAA] treatment with no possible benefit might outweigh the 
benefits for the minority who develop end stage liver disease.” (Koretz et al. 2015, emphasis added).  
Here, the case for restricted DAA treatment access is predicated on two interrelated assumptions: 
HCV is asymptomatic and the ‘benefits’ of an SVR are only measurable in clinical or population 
health terms.   
 
Traditionally, PWID have been a focus of treatment access dispute. Concerns about PWID suitability 
for interferon-based regimes have been framed in terms of toxicity, multi-morbidities, adherence 
and re-infection, at times masking deeper concerns about the ‘worthiness’ of PWID for treatment 
(Rhodes et al., 2013). A growing body of literature both exposes and refutes these concerns, 
demonstrating: adherence and successful outcomes; low re-infection occurrence; and the citizenship 
work undertaken by PWID attempting treatment access (Grebely et al., 2011; Rhodes et al., 2013). 
Most influential in rehabilitating the image of PWID as a priority treatment population, has been the 
modelling work on which the vision of viral elimination is based (Martin et al., 2013). Here treatment 
is operationalised as a prevention strategy promising significant reductions in incident infections and 
population prevalence. The advent of DAA therapies, with their reduced risk profile, enhances this 
public health potential.  
 
We can see, therefore, the emergence of discursive shift in the HCV treatment landscape, one 
informed by and impacting on questions of treatment prioritisation. This shift, from ‘managing risk 
and difficulty’ (‘difficult patients’, toxic regimes, uncertain efficacy, complex monitoring) to 
‘managing expense and expectation’ (expectant patients, efficacious regimes, cost and capacity 
restrictions) is nested within a broader aspirational discourse of biomedical innovation and promise. 
The visions associated with this promise are framed in population-health terms, with a specific focus 
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on those who are very ill and on those who are engaging in risk practices. This paper engages with 
the assumptions underpinning these visions to explore the concept of ‘patient important benefit’, 
with a focus on the populations often obscured or negated in DAA treatment prioritisation debates. 
Data are generated from interviews with a range of people seeking HCV treatment, to explore 
participants’ narratives of HCV treatment expectation and map their anticipatory accounts to those 
of post treatment ‘benefit’. Many – no longer injecting, with minimal to moderate fibrosis (Metavir 
stage <F3) – fall outside current treatment prioritisation scenarios and into the category of patients 
requiring ‘expectation management’.   
 
METHODS  
This paper draws on longitudinal qualitative data generated for a study exploring HCV treatment 
transitions, decision-making, support needs and service delivery from 2012 to 2015. The study 
received ethical approval from National Research Ethics Service London-Chelsea (12/LO/0652) and 
London School of Hygiene and Tropical Medicine Research Ethics Committee (6115). Participants 
provided signed consent prior to data collection, received a £20 reimbursement for each interview 
and are assigned pseudonyms.  
 
Sites & participants 
Sites comprised two large HCV treatment hospitals and two linked drug treatment services in London. 
People living with HCV were recruited through site providers, and were required to have received a 
HCV specialist referral and to be available for interview before treatment commencement. Sampling 
was purposive and theoretical: aimed at maximising variation in age, ethnicity and eligibility for 
different treatment options (determined by HCV genotype, previous treatment experience and extent 
of liver damage) and, as time progressed, informed by early analytic questions and gaps. Participants 
were not purposively sampled for injecting history, but diversity in this category was also realised. 
Participants with HCV comprised 23 men and five women, from 27 to 63 years old (average 46). The 
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majority (n=18) identified as White British. Twelve reported former drug injecting, five current 
injecting (within last 6 months) and eleven reported never injecting. In addition, 10 providers were 
interviewed. They were eligible if they worked at one of the sites and were directly involved in HCV 
treatment provision. Providers comprised four consultant hepatologists and six clinical nurse 
specialists, recruited through researcher contact. This paper draws on analyses from the interviews 
with people living with HCV. 
 
Data generation and analysis 
The primary data generation methods were in-depth interviews with patients and providers and 
ethnographic observations in nurse-led HCV clinics. Observations explored the dynamics of patient-
provider communication, information provision and treatment processes in situ, enabling 
triangulation through observing events also accounted in interviews. The initial interview guide was 
informed by the relevant literature and previous studies (cf. Harris et al., 2013) and modified for 
each interview cycle. Interviews were conducted by one researcher (MH) and took place between 
October 2012 and November 2015. Participants with HCV were interviewed in person up to five 
times each, at approximately three month intervals up until 18 months’ post-treatment, dependent 
on treatment duration, outcome, and participant availability. Providers were interviewed once; 
resulting in a corpus of 84 interviews. Interviews were in-depth, of 90 to 120 minutes’ duration, and 
audio-recorded with participant consent. Participants were invited at baseline to narrate their 
journey from HCV diagnosis (or acquisition) to the present date, with questions asked regarding 
medical experiences, treatment anticipations/decisions and day-to-day HCV impact. Follow up 
interviews addressed treatment perceptions/experiences; barriers and enablers to treatment 
commencement and completion and perceptions of the shifting treatment landscape. Providers 
were invited to talk about their perceptions of the changing treatment landscape; treatment 
decision making and prioritisation views and experiences.  
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Audio-recordings were transcribed verbatim and entered into NVivo10.  Observational notes and 
interview transcripts were coded as collected to inform subsequent data collection and analysis. 
Thematic coding was conducted by one researcher (MH) and comprised five stages: 1) data 
familiarisation, generating analytic memos, case summaries and follow-up questions; 2) first level 
“top down” (Saldana, 2015) coding of interview and observation data into low inference descriptive 
categories; 3) line-by-line open coding within each category concentrating on the generation of data 
driven and in vivo codes; 4) focused coding within each category reducing and refining open codes; 
5) Cross-sectional mapping of developed codes within and across overarching themes, and 
longitudinally by case with particular analytic focus on changes over time.   
 
This aim of this paper is to present analyses pertaining to participant treatment decision making, 
expectations and outcomes in a period of HCV biomedical transition and, through doing so, to 
explore the relevance and fit of contemporary public health discourses regarding ‘patient important 
benefits’ and HCV treatment prioritisation for this population.  
 
FINDINGS 
Treatment decision-making 
The nurse turns her chair to face Connor and says there are two options – the protease 
inhibitors with interferon, but also clinical trials coming up of the new interferon free drugs ... 
For him “to think about” – there will be no injection and up to 4 pills a day. He says “I just 
want to get started as quick as I can” … The one reason he doesn’t want to enter the trial is 
the possible delay in starting treatment. (Observation notes, Dec 2012) 
 
Throughout the study period the promise of more effective and tolerable DAA HCV treatments was 
on the horizon. The standard of care in the participating hospitals at study commencement was 
triple therapy (interferon, ribavirin, protease inhibitor) for people with HCV genotype one, and 
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interferon and ribavirin for those with genotypes two and three. The first-generation protease 
inhibitors (PIs) Telaprevir and Boceprevir, were a new treatment addition – approved for UK use in 
2012. Although these PIs improved treatment efficacy, they added to the side effect and monitoring 
burden. Observations of the clinical encounter illustrated that that the option of treatment deferral 
was generally provided to patients – albeit with an uncertain timescale for DAA availability. Those 
who met the criteria for DAA clinical trials or compassionate access were provided with this option. 
Of the participants’ ineligible for a trial or compassionate access, only one chose to wait for an all-
oral DAA regime, due to the potential exacerbation of his mental health condition by interferon.  
 
Twenty-two of the 28 patient participants commenced treatment during the study duration. Ten 
participants (genotype one) commenced a 24-48 week regime comprising interferon, ribavirin and a 
protease inhibitor. Six participants (genotype three) commenced a 24 week course of interferon and 
ribavirin. Two participants entered clinical trials and four qualified for compassionate access to DAA 
treatment. For eight participants, these initial treatment rounds were unsuccessful. Sixteen of the 22 
participants (72%) had a successful treatment outcome, with three experiencing post-treatment 
relapse, and three discontinuing due to non-response, imprisonment or poor adherence. Six 
participants (all drug treatment service clients) did not commence treatment during the study 
period, although all but one expressed a desire to start immediately.  
 
Treatment urgency  
Of note, was not only the decision by most participants to commence interferon-based therapy, but 
the urgency with which this decision was framed. Several participants, with mild to moderate liver 
fibrosis, could have safely deferred treatment. Indeed, in the clinical encounter, there was much to 
put patients off choosing the currently available regimens:  
The nurse tells him about side effects: flu-like symptoms and mood changes, including 
getting tearful and depressed. He might experience difficulty concentrating and/or sleeping, 
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dry skin, dry eyes, persistent thirst and skin rashes. Skin rashes are concerning if they spread 
very quickly, particularly if accompanied by a temperature or blistering of the mucous 
membranes. Regular blood tests will enable monitoring of complications such as anaemia 
and thyroid changes. As “in a very small amount of people there can be permanent thyroid 
damage”. Then: “I have saved the best for last – anal pain! The treatment is excreted 
through your poo so that can be sore and itchy”. (Observational notes, Nov 2013) 
Given this litany of misery it is surprising anyone chose treatment at all. However, most were 
undeterred. Ryan opted for 48 weeks of triple therapy with Teleprevir rather than waiting for the 
possibility of an easier regime: “I’d get rid of it straightaway … I’d seen what it said about the side-
effects and I thought, I don’t care … I just said, get me on it. Now!” Aisha refused a clinical trial in 
case it prolonged her start date: “I have to get the treatment, I got the disease so I have to take the 
treatment .... I just want to start now”. Omar framed treatment as an unquestioned imperative: “if 
you find out you have anything wrong in your body, you must be starting treatment”. For Moira, 
HCV was conceptualised as a colonising ‘other’ which required immediate removal: “Can I start 
treatment … I want to not let this virus thrive in me anymore, I want to do it now.”  
 
For many, the post-diagnosis period was a time of limbo – of stasis: “I don’t want my life on hold for 
any longer” (Bella). Here, treatment held the promise of progress, of new possibilities. While 
acknowledged as unpleasant, it was necessary to action immediately: “I just want to get it done … I 
just want to get it out of the way, I don’t want to be pending or wait a few years.” (Taj). Waiting was 
‘messing about’, it contravened a sense of the active, purposeful self: 
I’m looking forward to getting started and getting it over with, I mean that’s me, if I’m going 
to do something I want to get it done … I don’t want to fanny about, mess about, I’d rather 
get it done and then it’s done, straight down the line. (Bella) 
With reference to the clinical literature, this treatment urgency is understandable and actionable for 
people with advanced liver fibrosis. It aligns with the premise that “the avoidance of end stage liver 
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disease is a primary patient concern” (Innes, Goldberg, Dillon, et al., 2014). How then – for 
participants with a variety of disease stages – were the benefits of treatment conceptualised? What 
factors informed this urgency?  
 
Treatment hopes and expectation  
Participants accounted for HCV treatment urgency in relation to three interrelated narratives of 
hope and expectation. Treatment promised: social reconnection; social redemption from the drug 
using past; and a return to ‘normality’.  
 
Social reconnection  
Ivor’s account references all three expectations – reconnection, redemption and a return to 
normality. For Ivor, ‘normality’ is framed as a life without drugs and without HCV. Having ceased 
injecting and recently weaned himself off methadone, HCV was all that stood in the way of getting 
“back to normal”. By facilitating a return to normality, treatment also held the promise of 
reconnection: 
I have a son from my country and I want back for my son. I want back to normal without 
anything, without drugs, without the hepatitis … I’m not close with his mother. I tell her what 
I’m having, HCV. It’s not nice.  Because she tells me “oh no, you don’t see your son, because 
it’s infection” (Ivor).  
Like Ivor, Ryan spoke of social dislocation due to transmission fears. Although aware that HCV is 
rarely transmitted heterosexually, Ryan ceased all sexual relationships after diagnosis – an action 
which, for him, meant the end to life as he knew it: 
I found out I got hep C … that’s it, my life’s over, that means women are gone … I’m scared of 
giving it to them and I think to myself, if I can get rid of it I don’t have to worry … It was the 
biggest [treatment incentive] for me. Definitely, quite far and away the biggest one (Ryan).  
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Ryan characterised the two years between diagnosis and treatment commencement as stasis. For 
this time his life “completely stopped”. Treatment was viewed with hope – it held the promise of 
movement, of reconnection and continuance. 
 
Garry and Connor spoke of similar hopes and constraints. Both men described diagnosis as 
constituting a biographical disruption, in large part driven by transmission fears and stigma: 
I knew what would happen when I told her [wife] … "we all sit at this side of the table and 
you can sit on the settee over there. Don’t play with the kids too rough”. “Don’t cuddle up at 
night” … "I’m not touching you, no, we ain’t going there". (Garry) 
Connor’s sense of self as infectious also impacted on his family interactions:  
I was a bit reluctant with [grandchildren]. Well because of the disease ... I like to play with 
them and have a rough and tumble. I haven’t been so close to them since I’ve had it ... it’s 
sad, especially when they jump and try and give me a cuddle. 
Perceptions of infectivity can be intractable – as Garry later stated, the provision of transmission 
information would not be enough to allay his wife’s concerns. Treatment was the only option.  
 
Relationships with others were central to treatment urgency accounts. In each of her four interviews 
Bella emphasised the importance of family and the role they played in her treatment decision-
making:  
Devastated for my children … devastation, not for dying because I don’t think there’s 
anything to be scared of, but it’s leaving my children, that was it for me.  
HCV evoked mortality concerns for some, particularly for those who were living with cirrhosis. Yet 
death itself was not conceptualised as the primary fear – but the leaving of loved ones behind:  
What’s going to happen if I die tomorrow? What’s going to happen to [partner] ...  I’ve got to 
put it back together, that’s who I worry about is my partner. (Bobby) 
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For these participants’ treatment holds the hope of ‘putting it back together’ – of mending fractured 
relationships and continuing those already strong.  
 
Redemption and return 
HCV has a strong connection with injecting drug use in both the academic literature and the public 
imagination. This linkage, if not conflation, acts in specific ways to constitute the meanings and 
responsibilities associated with the virus (Fraser & Seear, 2011). As Bella articulated: 
[With cancer] you wouldn’t be isolated would you? You’d just be an unlucky cancer victim. 
This way you’ve brought it on yourself through sex and drugs.  
The responsiblising of HCV transmission and associated binary demarcation of people with HCV into 
‘innocent’ or ‘guilty’ ‘victims’ is reflected in participant narratives of redemption – whereby HCV 
treatment offers a symbolic break with the past, either solidifying or providing the foundation for 
drug use cessation:  
I’ve got to stay on it [treatment] and I’ve got to persevere with whatever I’ve got coming … I 
don’t really want to stop because I want to sort myself out and I want to come off the 
Methadone as well. I want to come off all drugs. (Bobby) 
Here, HCV treatment is part of a broader project of ‘sorting out’ the self.  Perseverance in the face of 
adverse and ongoing side effects demonstrates, to the self and others, the ability to tackle other 
prolonged rigors (such as methadone withdrawal) and, in doing so, facilitate a new redeemed and 
responsible self. 
 
Liam and Declan also framed HCV treatment as enabling change and solidifying life transformation: 
You can be 110% sure that I will carry on with the treatment because I want rid of this 
affliction, be it self-afflicted … I thought new treatment, new start. (Liam) 
If I can get rid of the hep C then I know I’m on the way back … I know I can come off the 
methadone, it’s just this. (Declan)  
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Treatment simultaneously offers a ‘new start’ and a ‘return’ – a return to ‘normality’ and the social 
body. Although Declan evokes return: “I’m on the way back”, his narrative also evidences a tension 
between ‘return’ and the unfamiliarity of this desired ‘normal’ state: “I’ve never had a normal life in 
42 years and this is my time to get me normal life back together.”  
 
HCV fractures ‘normality’ not only due to its symbolic association with drug injecting and the impact 
of contagion fears on social relationships, but also because of its embodied, physical effects. 
Ubiquitously described in the literature as ‘asymptomatic’ (e.g. Doyle et al., 2015), these physical 
effects rarely receive validation or acknowledgement:   
I find it annoying … people don’t actually realise how much it really does affect you. The 
worst thing is no energy … it knocks it out of you and you just don’t feel like doing anything 
and it just kills it all, ever so slowly and then you realise it. (Harry) 
Bobby spoke of how HCV had rendered his body foreign to him. Treatment not only offered the 
hope of sustained life with his partner, but of inhabiting his body as he used to: “I might have a few 
years left still and I want to feel good … I’m in bad shape … I mean I used to be a fighter.”  
 
Treatment outcomes 
Participant narratives demonstrated an extraordinary investment in the promise of HCV treatment – 
with treatment urgency figured in terms of resurrecting social relationships, enabling drug use 
cessation and providing a return to ‘normality’. In the light of calls for ‘patient expectation 
management’ it is pertinent to ask if these hopes were realised. Did treatment live up to its 
promise? Was the urgency with which participants framed their decision warranted? The 
longitudinal method of the research enables an exploration of these questions. 
 
Reconnection: exceeding the social 
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Desires and hopes for reconnection prior to treatment commencement were primarily figured in 
terms of social relationships and negating transmission fears and stigma. For Garry, Bobby and Ivor, 
treatment was either unsuccessful or interrupted by incarceration. Their reconnection hopes and 
expectations remained unrealised. For those with successful outcomes, social reconnection 
expectations appeared fulfilled: “It’s amazing … I’m clean. I don’t feel like a leper anymore” (Bella), “I 
pick them up and play with them [grandchildren] now” (Connor), “I’m fixed so I don’t have to worry 
about how I deal with people like I was before” (Ryan). 
 
While pre-treatment reconnection hopes were framed in terms of the social, participant’s post-
treatment accounts drew on a broader frame of reference. Connor described treatment success as 
providing not only a reconnection with others, but with a previously hidden side of the self: 
[Before treatment] foggy, like if I watched a sad film, nothing, but if I watch it now I get the 
tear roll down. Never had it before. I felt it but not connecting properly …. I didn’t realise how 
ill I was. It [HCV] affected my brain, it affected my sex drive, it affected all parts of my body … 
it’s all gradually reappearing, it’s like being born again … it’s funny how you get used to 
something and don’t realise.  
Moira also spoke of a renewed embodied connection:  
 My mood is different, my thinking is different, it’s hard to explain but I feel like a different 
person, I feel like the person I used to be some years ago … I was overwhelmed with the 
symptoms but not recognising them and putting them down to different things.  
 
Return and redemption: a reappraisal  
These narratives of rebirth and renewal are both determined by and trouble the biomedical 
discourse of HCV as ‘asymptomatic’. It is only once the virus is cleared that its symptoms become 
evident. This reappraisal of what it was to be ‘normal’ was common to the majority of participants 
16 
 
who cleared the virus. Thus ‘normality’ was framed not so much as a ‘return’ but as a reawakening. 
As Bella said:  
You can see then if you look back … you can see and pick out things … It was the illness, but 
you don’t know at the time. It’s your normal so you don’t know any different. 
For Ryan, HCV treatment precipitated an unexpected, and sustained, break from his heavy drinking – 
the old ‘normal’: 
I’m thinking “what is gonna be normal?” Because I’m not drinking, that’s not normal for a 
start. And I probably won’t go back to it. I don’t think I’ll go back to the way I was, no.  
Liam’s reference to ‘normal’ speaks to the realisation of his redemptive hopes (“new treatment, new 
start”). Treatment success constituted a final break with his drug using past: “I’m glowing with 
happiness … I have now the normal worries of life, what people have”. 
 
Expectations: exceeded and constrained 
For many, the post-treatment experience exceeded expectations. Treatment success, in and of itself, 
permitted a future: 
None of this would have happened if I hadn’t done the treatment, I wouldn’t have got fixed, 
I wouldn’t have sorted me drinking out and I wouldn’t have had any future … I’ve got a 
future now. (Ryan) 
For some, embodied inscriptions of marginality were resistant to treatment success. Connor spoke 
of how HCV, even in its absence, still made him “feel dirty”: “It’s associated with drug addicts, 
prostitution, you’ve no getting away from it.” Connor’s overarching post-treatment narrative was of 
rebirth and renewal. This slightly disjunctive statement illuminates the stickiness of HCV stigma – a 
residual underbelly of shame in an otherwise sanguine account.   
 
For Kaiser, HCV stigma was not only sticky but scarring. When asked if there was “any spark of light” 
in having cleared HCV, he replied:  
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No, because the scarring’s already there. Mental scarring … things that she said to me that, 
even though I’ve cleared the virus, still hurt, mentally ... It doesn’t just go away. 
This is not an account of dashed expectation. Kaiser’s pessimism preceded treatment 
commencement – and was not alleviated by its success. In this respect ‘clearing’ or ‘curing’ HCV is 
not clear cut. While biological markers can indicate absence, scars – both mental and physical (those 
on the liver and others less tangible) might remain. As Pedro, at seven months’ post treatment, 
illustrates: 
I am tired, my mood is very low. I am sad about that. My symptoms are the same, worse 
than before. … I am pleased the HCV is gone, but I am very confused … Apparently I am not 
sick, but at the same time I am feeling worse than before. 
Here, the post treatment period is one of heightened liminality. No longer officially ill, Pedro and 
Kaiser continue to live encumbered with the memory of the virus. 
 
Discussion 
At a time of HCV treatment transition, most participants chose to commence a complex and 
potentially debilitating interferon-based regime rather than wait for the DAAs. This is notable 
regarding participants with minimal fibrosis, for whom treatment deferral and ‘expectation 
management’ are increasingly proposed (Innes, Goldberg, Dillon, et al., 2014; Rice, 2015). 
Commencing treatment was spoken of with urgency – as holding the promise of movement from a 
place of stasis and disconnection to the opening up of multiple possible futures. For some, these 
expectations were exceeded – with accounts of reconnection not only to the social, but to a 
previously unattainable self. For others, these expectations remained unrealised – either due to 
treatment failure, or because of the residual stickiness of HCV stigma and symptoms. Participant 
accounts of treatment expectations and outcomes do not accord with predominant prioritisation 
discourses in that they gave little weight to clinical markers, such as stage of liver disease. Notably, 
the healing promise of treatment was primarily existential – it could ‘fix’, ‘sort out’ and mend a 
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fractured self. As explored below, these accounts are produced in conjunction with experiences of 
specific treatment systems and cultural narratives of biomedical promise and personal redemption, 
yet they can also be read in terms of social suffering (Honkasalo, 2006) – a suffering rarely 
acknowledged in treatment prioritisation debates.  
 
The making and managing of expectations 
Accounts emphasising perseverance and/or the promise of rehabilitation are common to the 
qualitative HCV treatment literature (Clark & Gifford, 2015; Harris et al.,2013; Rance & Treloar, 2014; 
Rhodes et al., 2013) and intertwine in study participant narratives. Taking on a difficult interferon-
based treatment now, as opposed to an easier DAA therapy later, accords with cultural scripts of 
redemption through personal trial (Clark & Gifford, 2015; Coupland & Maher, 2010) and 
demonstrates an active responsible citizenship (Rhodes et al., 2013). This demonstration aligns with 
the forms of subjectivity accepted and performed by treatment systems (Fraser & Seear, 2011) 
where most treating clinicians favour individuals who are perceived to be responsible and stable, 
particularly in terms of recovery from drug use. In order to obtain treatment, certain performances 
are made; those unwilling or unable to demonstrate stability and perseverance are required to wait.   
Treatment narratives are, therefore, local productions in context – they reflect attributes of the 
institutional health policies, services and cultures in which treatments are realised (Clark & Gifford, 
2015). 
 
It is for this reason, among others, that a sample was selected who were yet to commence 
treatment, with the longitudinal design allowing analysis of both temporal change in 
expectation/experience and of the circuits of exclusion and inclusion that determined treatment 
involvement. Given pervasive interferon treatment barriers (Harris & Rhodes, 2013; Treloar et al., 
2013), it is perhaps unusual that such a high percentage commenced treatment – particularly during 
this time of biomedical transition. The study sampling criterion of specialist referral requires 
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acknowledgement here, with those reaching this stage likely to have demonstrated treatment 
interest and/or be less impacted by institutional barriers to treatment access. The six participants 
not to commence HCV treatment were all drug treatment service clients. For all but one, their desire 
to commence treatment was high. Structural barriers such as homelessness can be seen to preclude 
uptake for some (see Harris & Rhodes, 2016), yet this also reflects institutional preferences for 
‘stability’ as outlined above.  
 
With the move from interferon to DAA treatments, and associated discursive shift from ‘managing 
risk and difficulty’ to ‘managing expense and expectation’, prioritisation preferences are subject to 
change. Increased acceptance of PWID as a priority population has coincided with treatment 
deferral recommendations for people with mild disease who are not injecting. This is a notable shift, 
one that draws on a population health appraisal of benefit and need. The benefits posited are for 
health systems (treat advanced disease = reduce SLM burden) and populations (treat PWID = reduce 
disease prevalence) rather than assessed in individual terms. As outlined in this paper, these public 
health visions do not necessarily resonate with those managing HCV in their daily lives.  
 
Rationed expectations and constructed futures 
Regarding a future of managed expectations, the choices made by participants in this study are 
potentially prescient.  For those marginalised, injecting or not, ‘choice’ is often circumscribed.  Many 
had been waiting for a treatment opportunity, and the timescale for DAA access was unclear. 
Protease inhibitors were ‘new drugs’ – holding promise of a successful outcome, along with 
increased toxicity and risk. Moreover, expectations of access to better treatments were rationed.  
Accounts of rationed expectation and biotechnical embrace intertwined in participants’ narratives; 
with analysis of the latter opening up perspectives on the former.  The term ‘biotechnical embrace’ 
describes the affective response of clinicians and patients to new biotechnologies and experimental 
treatments (Good, 2001) and is apposite to convey participants’ emotional investment in the 
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promise of both the old and the new to effect existential change.  For many, interferon-based 
therapies were embraced as offering reconnection – both to the self and the social body. Hopes of 
reconnection, and aspirational accounts of ‘normalcy’, are premised on feelings of disconnection – 
of partial and precluded citizenship. A questionable citizenship status, accompanied by institutional 
practices of delay, can act to impede perceptions of entitlement to breakthrough drug 
developments.   
 
The differential structuring of imagined futures and entitlement to biomedical advance is of concern 
in a context where directives for treatment prioritisation can be opaque and open to clinician 
interpretation. For example, the recent NICE appraisal guidelines recommend access to all-oral DAA 
regimens for people with HCV genotypes one and four but for access to be prioritised for people 
with the highest unmet clinical need (National Institute for Health and Care Excellence, 2015). What 
constitutes clinical need is not defined, however the term implies privileging clinical markers of liver 
disease over and above lived experience of distress. The absence of a definition can provide leeway 
for multi-disciplinary teams to consider treatment benefit complexities, yet this also poses problems. 
As a review of ‘bedside rationing practices’ found, clinicians often implicitly categorize patients, with 
treatment allocation decisions influenced by the patient’s age, their ability to exercise pressure and 
“their relative contribution to society” (Strech et al., 2008).  
 
Expected futures and their potential attainment are in this sense produced by treatment systems, 
public health policies and presentations of worth, stability and entitlement. The deployment of the 
latter are differentially influenced by class, education, wealth and social mobilisation (Novas, 2006). 
The construction of HCV as stigmatised, contagious, as associated with “drug addicts, prostitution”, 
precludes such mobilisation, particularly among people who are either criminalised due to their drug 
consumption practices, or who wish to distance themselves from such associations. The 
collectivising moment of biosocial citizenship, as instantiated by activism, is weak in relation to HCV 
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(Rhodes et al., 2013). While this can help to explain rationed expectations regarding the promise of 
future treatment and its personal attainment, it is important not to overlook or explain away the 
urgency with which commencing treatment now was articulated.  
 
Acknowledging social suffering 
Participants’ narratives evidenced an extraordinary investment in the power of the biomedical to 
effect existential change. While these accounts are inevitably influenced by cultural scripts of 
biomedicine as transformative (Good, 2001), they also express experiences of social suffering that 
require acknowledgement. Social suffering, as “the harms done to a person’s sense of social value 
and moral worth”, “takes place in relation to events and processes that are most meaningful for 
people’s lives, such as being in love, acquiring a sense of well-being or the ability to work” 
(Honkasalo, 2006: 28). Accounts of treatment urgency were primarily framed within these terms – as 
countering threats to what was at stake, what mattered. For Ivor, this was being able to see his son; 
for Ryan and Gary, being able to commence and sustain sexual relationships; for Connor, Gary and 
Bella – to enjoy uninhibited play with their children and grandchildren. In these terms, the 
anticipated and realised benefits of treatment success were immeasurable. We need to ask 
therefore, if treatment benefit can be purely conceptualised in clinical terms, and – in relation to 
treatment prioritisation policies – is it ethical to do so?  
 
It can be argued that the examples provided above evidence misconceptions; that this suffering 
could be ameliorated by information provision as much as treatment. HCV is very rarely 
heterosexually transmitted and not contracted through practices such as hugging and playing. This 
however, is not simply a matter of ignorance; of inadequate knowledge transfer. While many 
participants realised the risks articulated were minimal, the symbolic weight of HCV stigma 
constrained their actions. Normalcy talk references this symbolic weight; it evidences awareness of 
occupying a socially undesirable status (Nettleton, Neale, & Pickering, 2013). Prior to treatment 
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‘normality’ was aspirational rather achieved – life without, rather than with, HCV. HCV connotes 
abjection, due to associations with injecting drug use, but also contagion and physical debility 
(Harris, 2009). For the symptomatic, ubiquitous references to HCV as ‘asymptomatic’ in clinical 
practice and literature (Doyle et al., 2015) can amplify experienced disconnection and stigma (Harris, 
2009). Although there is a literature referencing and quantifying HCV quality of life (Younossi et al., 
2015; Whiteley et al., 2015), this concept lacks potency in expressing the social suffering 
experienced by many. 
 
Conclusion  
In this period of transition from ‘managing risk and difficulty’ to ‘managing expense and expectation’ 
it is crucial that the impact of HCV on the social is accorded weight in clinical literature and practice. 
The existential promise of treatment to alleviate social suffering can render expectations impervious 
to clinical management – posing problems for clinicians assigned this task. Treatment systems 
fashion the accounts of those engaged with them, as well as pre-selecting research accounts 
available to access. Changing circuits of biomedical inclusion and exclusion may mean those 
previously deemed ‘unstable’ become prioritised for treatment, producing different accounts of 
expectation and imagined futures. For most participants in this study, their treatment urgency was 
deemed not clinically necessary, and indeed – in an era of biomedical innovation – could be 
perceived as self-defeating. However, in a context of rationed expectation, this urgency operated to 
counter threats to what mattered: offering the promise of reconnection, continuance and return – 
both to the social body and a previously unattainable self.  Until there is a fundamental change in 
associations of HCV with the abject it is imperative that these social benefits are acknowledged in 
prioritisation debates.  
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